Loading…
Hester Biosciences (HESTERBIO)₹2,309−2.39%Pharmaceuticals
Hester Biosciences is compared with the 10 closest in size in Pharmaceuticals (229 companies in the industry). It has a P/E of 14.4 against a peer median of 35.4, and ROCE of 15.0% against a peer median of 16.0%, and latest-quarter sales growth of −8.5% against a peer median of 19.5%. By market cap it is #8 of 11 in this set.
As of · Peer set: 10 closest in size in Pharmaceuticals
| Company | M-cap (₹ Cr) | P/E | ROCE % | ROE % | Debt / equity | Div. yield % | Sales (₹ Cr) | Net profit (₹ Cr) | Qtr sales growth % | Qtr profit growth % | Compare |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sakar Healthcare | 2,284 | 53.4 | 12.0 | 10.0 | 0.13 | 0.0 | 251 | 30 | 49.9 | 119.8 | vs HESTERBIO |
| Fredun Pharmaceuticals | 2,245 | 49.1 | 21.0 | 15.6 | 0.81 | 0.0 | 636 | 33 | 90.0 | 85.8 | vs HESTERBIO |
| Sai Parenterals | 2,237 | 156.2 | 5.0 | 4.9 | 0.96 | 0.0 | 382 | 14 | 435.6 | 455.2 | vs HESTERBIO |
| Panacea Biotec | 2,206 | — | −2.0 | −2.4 | 0.03 | 0.0 | 641 | −7 | 19.5 | −44.3 | vs HESTERBIO |
| Beta Drugs | 2,089 | 39.0 | 19.0 | 18.9 | 0.11 | 0.0 | 384 | 41 | 33.0 | 58.3 | vs HESTERBIO |
| Indoco Remedies | 2,025 | 63.4 | 1.0 | −9.4 | 1.17 | 0.1 | 1,848 | −99 | 7.2 | — | vs HESTERBIO |
| Windlas Biotech | 2,007 | 30.8 | 16.0 | 12.2 | 0.06 | 0.6 | 906 | 66 | 18.2 | 0.0 | vs HESTERBIO |
| Hester Biosciences | 1,963 | 14.4 | 15.0 | 15.9 | 0.54 | 0.5 | 332 | 57 | −8.5 | 471.0 | — |
| Venus Remedies | 1,941 | 15.9 | 21.0 | 15.7 | 0.02 | 0.7 | 769 | 103 | 13.3 | 30.0 | vs HESTERBIO |
| Syncom Formulations (India) | 1,885 | 21.6 | 27.1 | 20.2 | 0.00 | 0.5 | 488 | 76 | 7.7 | 56.3 | vs HESTERBIO |
| NGL Fine-Chem | 1,814 | 31.7 | 19.0 | 17.4 | 0.37 | 0.1 | 500 | 48 | 33.8 | 100.0 | vs HESTERBIO |
| Peer median | 2,025 | 35.4 | 16.0 | 15.6 | 0.13 | 0.1 | 500 | 41 | 19.5 | 72.0 |
Listed companies closest to Hester Biosciences in Pharmaceuticals include Sakar Healthcare, Fredun Pharmaceuticals, Sai Parenterals, Panacea Biotec, Beta Drugs, Indoco Remedies, Windlas Biotech, Venus Remedies.
Sakar Healthcare, with a market cap of ₹2,284 Cr.
Hester Biosciences trades at a P/E of 14.4; the median of its peer set is 35.4. A P/E above or below the median is a description, not a judgement on value.
Hester Biosciences' return on capital employed is 15.0%, below the peer median of 16.0%.